Twin Peaks Wealth Advisors’s Royalty Pharma RPRX Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-64	Closed	-$3.07K	–	1777
2026 Q1	$3.07K	Buy	+64	New	+$2.8K	﹤0.01%	1564
2025 Q3	–	Sell	-23	Closed	-$820	–	1687
2025 Q2	$820	Buy	+23	New	+$762	﹤0.01%	1815

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Twin Peaks Wealth Advisors's RPRX Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Royalty Pharma (RPRX) in Q2 2026, closing a stake of 64 shares — an estimated $3.07K sold.

Twin Peaks Wealth Advisors first reported a position in RPRX in Q2 2025 and held it in 2 quarters. The position peaked at $3.07K in Q1 2026. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Twin Peaks Wealth Advisors reported no remaining Royalty Pharma position as of Q2 2026 after selling out during the quarter.
Twin Peaks Wealth Advisors sold 64 Royalty Pharma shares in Q2 2026, an estimated $3.07K.
Twin Peaks Wealth Advisors first reported a position in Royalty Pharma in Q2 2025 and held it in 2 quarters.
Twin Peaks Wealth Advisors's Royalty Pharma position peaked at $3.07K in Q1 2026.
641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.